Pomerantz LLP Files Class Action Lawsuit Against Indivior PLC New York, NY / Accesswire / September 27, 2024 Pomerantz LLP announces that a class action lawsuit has been filed against Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) and certain officers. The class action, filed in the United States District Court for the Eastern District…
After days of bulls’ dominance in the crypto market, many cryptocurrencies have felt an uptrend The Rise of Ethereum After experiencing saturation earlier this year, Ethereum has bounced back impressively in recent days. This recovery is particularly important in September, a month known for the market’s poor performance. The gains made by Ethereum have been…
Are you a Moderna Investor Who Suffered Losses? Here’s What You Need to Know Introduction Hey there fellow investor! Have you recently experienced losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024? If so, you’re not alone. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson is here to help…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In New Fortress To Contact Him Directly To Discuss Their Options Investigation Against New Fortress Energy Inc. If you suffered losses exceeding $50,000 in New Fortress between February 9, 2024, and August 8, 2024 and would like to…
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD About Dupixent Approval Dupixent has been approved by the US Food and Drug Administration (FDA) as the first-ever biologic medicine for patients with chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. This approval is a significant milestone for the…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Five Below To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESSWIRE / September 27, 2024 / If you suffered losses exceeding $100,000 investing in Five Below stock or options between December 1,…
Exciting News for Drug Delivery Innovation! Lexaria Bioscience Corp. Makes Breakthrough with DehydraTECH-processed tirzepatide Hey there fellow science enthusiasts and health buffs! Have you heard the latest buzz in the world of drug delivery technology? Lexaria Bioscience Corp. has just announced a major milestone with the approval of a human pilot study #3 to test…
Vail Resorts’ Strategic Transformation Plan Shows Promise Amidst Challenges Efforts to Address Weather and Labor Challenges Vail Resorts’ Q4’24 results reveal a concerted effort to combat the challenges posed by unpredictable weather patterns and labor shortages. The Resource Efficiency Transformation Plan is a bold move aimed at streamlining operations, improving margins, and enhancing guest experiences….
